

REFERENCES

- Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Mollapour Siasakht, M., Farhadi, A., ... & Meshkat, Z. (2022). Mutations in SARS-CoV-2 structural proteins: A global analysis. *Virology Journal*, 19(1), 1-19. <https://doi.org/10.1186/s12985-022-01951-7>
- Abbas, A. K., Lichtman, A. H., & Pillai, S. (2019). Basic Immunology E-book: Functions and Disorders of the Immune System (6th ed.). Elsevier Health Sciences.
- Arora, S. K., & Aryandra, A. (2020). Epitope Based Vaccine Designing—A mini review. *J. Vaccines Immunol*, 6, 038-041. <https://doi.org/10.17352/jvi.000036>
- Astuti, I. (2020). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 14(4), 407-412. <https://doi.org/10.1016/j.dsx.2020.04.020>
- Aydin, S. (2015). A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. *Peptides*, 72, 4-15. <https://doi.org/10.1016/j.peptides.2015.04.012>
- Bhatt, P. R., Scaiola, A., Loughran, G., Leibundgut, M., Kratzel, A., Meurs, R., ... & Ban, N. (2021). Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome. *Science*, 372(6548), 1306-1313. <https://doi.org/10.1126%2Fscience.abf3546>
- Blum, J. S., Wearsch, P. A., & Cresswell, P. (2013). Pathways of antigen processing. *Annual review of immunology*, 31, 443-473. <https://doi.org/10.1146%2Fannurev-immunol-032712-095910>
- Carabelli, A. M., Peacock, T. P., Thorne, L. G., Harvey, W. T., Hughes, J., COVID-19 Genomics UK Consortium de Silva Thushan I. 6, ... & Robertson, D. L. (2023). SARS-CoV-2 variant biology: immune escape, transmission and fitness. *Nature Reviews Microbiology*, 21(3), 162-177. <https://doi.org/10.1038/s41579-022-00841-7>

Medhasi, S., & Chantratita, N. (2022). Human leukocyte antigen (HLA) system: genetics and association with bacterial and viral infections. *Journal of Immunology Research*, 2022. <https://doi.org/10.1155%2F2022%2F9710376>

Chakraborty, C., Bhattacharya, M., & Dhama, K. (2023). SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight against the next pandemic. *Vaccines*, 11(3), 682. <https://doi.org/10.3390%2Fvaccines11030682>

Cong, Y., Ulasli, M., Schepers, H., Mauthe, M., V'kovski, P., Kriegenburg, F., ... & Reggiori, F. (2020). Nucleocapsid protein recruitment to replication-transcription complexes plays a crucial role in coronaviral life cycle. *Journal of virology*, 94(4), e01925-19. <https://doi.org/10.1128/jvi.01925-19>

Diamond, M. S., & Kanneganti, T. D. (2022). Innate immunity: the first line of defense against SARS-CoV-2. *Nature immunology*, 23(2), 165-176. <https://doi.org/10.1038/s41590-021-01091-0>

Di, D., Dileepan, M., Ahmed, S., Liang, Y., & Ly, H. (2021). Recombinant SARS-CoV-2 nucleocapsid protein: Expression, purification, and its biochemical characterization and utility in serological assay development to assess immunological responses to SARS-CoV-2 infection. *Pathogens*, 10(8), 1039.

Dinesh, D. C., Chalupska, D., Silhan, J., Koutna, E., Nencka, R., Veverka, V., & Boura, E. (2020). Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid phosphoprotein. *PLoS pathogens*, 16(12), e1009100. <https://doi.org/10.1371/journal.ppat.1009100>

Dutta, N. K., Mazumdar, K., & Gordy, J. T. (2020). The nucleocapsid protein of SARS-CoV-2: a target for vaccine development. *Journal of virology*, 94(13), 10-1128. <https://doi.org/10.1128%2FJVI.00647-20>

Eisen, H. N. (2014). Affinity enhancement of antibodies: how low-affinity antibodies produced early in immune responses are followed by high-affinity antibodies later and in memory B-cell

responses. *Cancer immunology research*, 2(5), 381-392.

<https://doi.org/10.1158/2326-6066.cir-14-0029>

Embgenbroich, M., & Burgdorf, S. (2018). Current concepts of antigen cross-presentation. *Frontiers in immunology*, 9, 1643. <https://doi.org/10.3389/fimmu.2018.01643>

Gustiananda, M., Sulistyo, B. P., Agustriawan, D., & Andarini, S. (2021). Immunoinformatics analysis of SARS-CoV-2 ORF1ab polyproteins to identify promiscuous and highly conserved T-cell epitopes to formulate vaccine for Indonesia and the world population. *Vaccines*, 9(12), 1459. <https://doi.org/10.3390/vaccines9121459>

Hardenbrook, N. J., & Zhang, P. (2022). A structural view of the SARS-CoV-2 virus and its assembly. *Current opinion in virology*, 52, 123-134. <https://doi.org/10.1016/j.coviro.2021.11.011>

Haq, I. U., Kruckiewicz, K., Tayyab, H., Khan, I., Khan, M., Yahya, G., & Cavalu, S. (2023). Molecular Understanding of ACE-2 and HLA-Conferred Differential Susceptibility to COVID-19: Host-Directed Insights Opening New Windows in COVID-19 Therapeutics. *Journal of Clinical Medicine*, 12(7), 2645. <https://doi.org/10.3390%2Fjcm12072645>

Hewitt, E. W. (2003). The MHC class I antigen presentation pathway: strategies for viral immune evasion. *Immunology*, 110(2), 163-169.

<https://doi.org/10.1046%2Fj.1365-2567.2003.01738.x>

Hu, B., Guo, H., Zhou, P., & Shi, Z. L. (2021). Characteristics of SARS-CoV-2 and COVID-19. *Nature Reviews Microbiology*, 19(3), 141-154. <https://doi.org/10.1038/s41579-020-00459-7>

Huang, Y., Yang, C., Xu, X. F., Xu, W., & Liu, S. W. (2020). Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. *Acta Pharmacologica Sinica*, 41(9), 1141-1149. <https://doi.org/10.1038/s41401-020-0485-4>

Hwang, J. R., Byeon, Y., Kim, D., & Park, S. G. (2020). Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development. *Experimental & molecular medicine*, 52(5), 750-761. <https://doi.org/10.1038/s12276-020-0435-8>

- Jamison Jr, D. A., Anand Narayanan, S., Trovão, N. S., Guarnieri, J. W., Topper, M. J., Moraes-Vieira, P. M., ... & Beheshti, A. (2022). A comprehensive SARS-CoV-2 and COVID-19 review, Part 1: Intracellular overdrive for SARS-CoV-2 infection. *European Journal of Human Genetics*, 30(8), 889-898. <https://doi.org/10.1038/s41431-022-01108-8>
- Janeway Jr, Charles A., Paul Travers, Mark Walport, and Mark J. Shlomchik. "Principles of innate and adaptive immunity." In *Immunobiology: The Immune System in Health and Disease*. 5th edition. Garland Science, 2001.
- Jarjour, N. N., Masopust, D., & Jameson, S. C. (2021). T cell memory: understanding COVID-19. *Immunity*, 54(1), 14-18. <https://doi.org/10.1016%2Fj.immuni.2020.12.009>
- Karnaukhov, V., Paes, W., Woodhouse, I. B., Partridge, T., Nicastri, A., Brackenridge, S., ... & Shugay, M. (2022). HLA variants have different preferences to present proteins with specific molecular functions which are complemented in frequent haplotypes. *Frontiers in Immunology*, 13, 1067463. <https://doi.org/10.3389/fimmu.2022.1067463>
- Kumar, S., Nyodu, R., Maurya, V. K., & Saxena, S. K. (2020). Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In *Coronavirus Disease 2019 (COVID-19)* (pp. 23-31). Springer, Singapore. https://doi.org/10.1007%2F978-981-15-4814-7_3
- Liu, D. X., Liang, J. Q., & Fung, T. S. (2021). Human coronavirus-229E,-OC43,-NL63, and-HKU1 (Coronaviridae). *Encyclopedia of virology*, 428. <https://doi.org/10.1016%2FB978-0-12-809633-8.21501-X>
- López-Muñoz, A. D., Santos, J. J., & Yewdell, J. W. (2023). Cell Surface Nucleocapsid Protein Expression: A Betacoronavirus Immunomodulatory Strategy. *bioRxiv*, 2023-02. <https://doi.org/10.1101%2F2023.02.24.529952>
- Maison, D. P., Deng, Y., & Gerschenson, M. (2023). SARS-CoV-2 and the host-immune response. *Frontiers in Immunology*, 14. <https://doi.org/10.3389/fimmu.2023.1195871>

- Martínez-Archundia, M., Ramírez-Salinas, G. L., García-Machorro, J., & Correa-Basurto, J. (2022). Searching Epitope-Based Vaccines Using Bioinformatics Studies. *Vaccine Design: Methods and Protocols*, Volume 3. Resources for Vaccine Development, 471-479. https://doi.org/10.1007/978-1-0716-1892-9_26
- Medhasi, S., & Chantratita, N. (2022). Human leukocyte antigen (HLA) system: genetics and association with bacterial and viral infections. *Journal of Immunology Research*, 2022. <https://doi.org/10.1155%2F2022%2F9710376>
- Miller, M. L., Chong, A. S., & Alegre, M. L. (2014). Mechanisms underlying transplantation tolerance. <https://doi.org/10.1016/B978-0-12-801238-3.00127-6>
- Mistry, P., Barmania, F., Mellet, J., Peta, K., Strydom, A., Viljoen, I. M., ... & Pepper, M. S. (2022). SARS-CoV-2 variants, vaccines, and host immunity. *Frontiers in immunology*, 12, 809244. <https://doi.org/10.3389%2Ffimmu.2021.809244>
- Möbs, C., & Schmidt, T. (2016). Research techniques made simple: monitoring of T-cell subsets using the ELISPOT assay. *Journal of Investigative Dermatology*, 136(6), e55-e59. <https://doi.org/10.1016/j.jid.2016.04.009>
- Naz, A., Shahid, F., Butt, T. T., Awan, F. M., Ali, A., & Malik, A. (2020). Designing multi-epitope vaccines to combat emerging coronavirus disease 2019 (COVID-19) by employing immuno-informatics approach. *Frontiers in Immunology*, 11, 1663. <https://doi.org/10.3389%2Ffimmu.2020.01663>
- Nelson, R. W., Beisang, D., Tubo, N. J., Dileepan, T., Wiesner, D. L., Nielsen, K., ... & Jenkins, M. K. (2015). T cell receptor cross-reactivity between similar foreign and self peptides influences naive cell population size and autoimmunity. *Immunity*, 42(1), 95-107. <https://doi.org/10.1016/j.immuni.2014.12.022>
- Pradana, K. A., Widjaya, M. A., & Wahjudi, M. (2020). Indonesians Human Leukocyte Antigen (HLA) distributions and correlations with global diseases. *Immunological Investigations*, 49(3), 333-363. <https://doi.org/10.1080/08820139.2019.1673771>

Praviningrum, A. F., Paramita, R. I., & Panigoro, S. S. (2022). Immunoinformatics approach for epitope-based vaccine design: Key steps for breast cancer vaccine. *Diagnostics*, 12(12), 2981. <https://doi.org/10.3390%2Fdiagnostics12122981>

Qaqish, A., Abbas, M. M., Al-Tamimi, M., Abbas, M. A., Al-Omari, M., & Alqassieh, R. (2022). SARS-CoV-2 antinucleocapsid antibody response of mRNA and inactivated virus vaccines compared to unvaccinated individuals. *Vaccines*, 10(5), 643. <https://doi.org/10.3390/vaccines10050643>

Qi, H., Liu, B., Wang, X., & Zhang, L. (2022). The humoral response and antibodies against SARS-CoV-2 infection. *Nature Immunology*, 23(7), 1008-1020. <https://doi.org/10.1038/s41590-022-01248-5>

Roche, P. A., & Furuta, K. (2015). The ins and outs of MHC class II-mediated antigen processing and presentation. *Nature Reviews Immunology*, 15(4), 203-216. <https://doi.org/10.1038/nri3818>
Röltgen, K., & Boyd, S. D. (2021). Antibody and B cell responses to SARS-CoV-2 infection and vaccination. *Cell host & microbe*, 29(7), 1063-1075. <https://doi.org/10.1016%2Fj.chom.2021.06.009>

Ross, S. H., & Cantrell, D. A. (2018). Signaling and function of interleukin-2 in T lymphocytes. *Annual review of immunology*, 36, 411-433. <https://doi.org/10.1146%2Fannurev-immunol-042617-053352>

Cruz-Tapias, P. C. J., & Anaya, J. M. (2021). Major histocompatibility complex: Antigen processing and presentation 2013.

Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021). Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. *Nature Reviews Immunology*, 21(8), 475-484. <https://doi.org/10.1038%2Fs41577-021-00578-z>

Sanchez-Trincado, J. L., Gomez-Perosanz, M., & Reche, P. A. (2017). Fundamentals and methods for T-and B-cell epitope prediction. *Journal of immunology research*, 2017. <https://doi.org/10.1155%2F2017%2F2680160>

- Santos-Mendoza, T. (2023). The Envelope (E) Protein of SARS-CoV-2 as a Pharmacological Target. *Viruses*, 15(4), 1000. <https://doi.org/10.3390/v15041000>
- Schmidt, M. E., & Varga, S. M. (2018). The CD8 T cell response to respiratory virus infections. *Frontiers in immunology*, 9, 678. <https://doi.org/10.3389/fimmu.2018.00678>
- Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020). Overview of immune response during SARS-CoV-2 infection: lessons from the past. *Frontiers in immunology*, 11, 1949. <https://doi.org/10.3389/fimmu.2020.01949>
- Sharifzadeh, M., Mottaghi-Dastjerdi, N., & Raad, M. S. R. (2022). A review of virus-like particle-based SARS-CoV-2 vaccines in clinical trial phases. *Iranian Journal of Pharmaceutical Research: IJPR*, 21(1). <https://doi.org/10.5812%2Fijpr-127042>
- Ten Broeke, T., Wubbolts, R., & Stoorvogel, W. (2013). MHC class II antigen presentation by dendritic cells regulated through endosomal sorting. *Cold Spring Harbor perspectives in biology*, 5(12), a016873. <https://doi.org/10.1101%2Fcshperspect.a016873>
- Ville, S., Poirier, N., Blancho, G., & Vanhove, B. (2015). Co-stimulatory blockade of the CD28/CD80-86/CTLA-4 balance in transplantation: impact on memory T cells?. *Frontiers in Immunology*, 6, 411. <https://doi.org/10.3389/fimmu.2015.00411>
- V'kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2021). Coronavirus biology and replication: implications for SARS-CoV-2. *Nature Reviews Microbiology*, 19(3), 155-170. <https://doi.org/10.1038/s41579-020-00468-6>
- Wang, C., Chen, L. Y., Lu, Q. B., & Cui, F. (2022). Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease. *Vaccines*, 10(6), 920. <https://doi.org/10.3390%2Fvaccines10060920>
- Williams, T. M. (2001). Human leukocyte antigen gene polymorphism and the histocompatibility laboratory. *The journal of molecular diagnostics*, 3(3), 98-104. [https://doi.org/10.1016%2FS1525-1578\(10\)60658-7](https://doi.org/10.1016%2FS1525-1578(10)60658-7)

- Wieczorek, M., Abualrous, E. T., Sticht, J., Álvaro-Benito, M., Stolzenberg, S., Noé, F., & Freund, C. (2017). Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. *Frontiers in immunology*, 8, 292. <https://doi.org/10.3389/fimmu.2017.00292>
- Wu, C. R., Yin, W. C., Jiang, Y., & Xu, H. E. (2022). Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. *Acta Pharmacologica Sinica*, 43(12), 3021-3033. <https://doi.org/10.1038/s41401-021-00851-w>
- Wu, W., Cheng, Y., Zhou, H., Sun, C., & Zhang, S. (2023). The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics. *Virology Journal*, 20(1), 1-16. <https://doi.org/10.1186/s12985-023-01968-6>
- Yadav, R., Chaudhary, J. K., Jain, N., Chaudhary, P. K., Khanra, S., Dhamija, P., ... & Handu, S. (2021). Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. *Cells*, 10(4), 821. <https://doi.org/10.3390%2Fcells10040821>
- Yang, H., & Rao, Z. (2021). Structural biology of SARS-CoV-2 and implications for therapeutic development. *Nature Reviews Microbiology*, 19(11), 685-700. <https://doi.org/10.1038%2Fs41579-021-00630-8>
- Zandi, M., Shafaati, M., Kalantar-Neyestanaki, D., Pourghadamayari, H., Fani, M., Soltani, S., ... & Abbasi, S. (2022). The role of SARS-CoV-2 accessory proteins in immune evasion. *Biomedicine & Pharmacotherapy*, 113889. <https://doi.org/10.1016%2Fj.biopha.2022.113889>
- Zhang, J., & Tao, A. (2015). Antigenicity, immunogenicity, allergenicity. *Allergy bioinformatics*, 175-186. https://doi.org/10.1007%2F978-94-017-7444-4_11
- Zhang, Z., Nomura, N., Muramoto, Y., Ekimoto, T., Uemura, T., Liu, K., ... & Shimizu, T. (2022). Structure of SARS-CoV-2 membrane protein essential for virus assembly. *Nature communications*, 13(1), 4399. <https://doi.org/10.1038/s41467-022-32019-3>

Zheng, J., Deng, Y., Zhao, Z., Mao, B., Lu, M., Lin, Y., & Huang, A. (2022). Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects. *Cellular & molecular immunology*, 19(2), 150-157.

<https://doi.org/10.1038/s41423-021-00774-w>